Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Menopausal Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison Study of PTHrP and PTH to Treat Osteoporosis

NCT00853723
View directory record Official record
Conditions
Osteoporosis
Interventions
Parathyroid hormone related protein(1-36), Parathyroid hormone (1-34)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Sep 2, 2026, 10:42 PM EDT
Completed Phase 2 Interventional

Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women

NCT00107016
View directory record Official record
Conditions
Breast Neoplasm
Interventions
RAD001, Letrozole 2.5mg, Letrozole 2.5mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
10
States / cities
Springdale, Arkansas • Long Beach, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2013 · Synced Sep 2, 2026, 10:42 PM EDT
Terminated Phase 2 Interventional Results available

Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.

NCT00611715
View directory record Official record
Conditions
Breast Cancer
Interventions
erlotinib hydrochloride, letrozole, fluorescence in situ hybridization, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
9
States / cities
Macon, Georgia • Hopkinsville, Kentucky • Paducah, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Sep 2, 2026, 10:42 PM EDT
Not yet recruiting Not applicable Interventional

Evaluation of the Effects of Lifestyle Medicine and Mindfulness-based Group Medical Visits on Stress, Microbiome, and Quality of Life in Women Experiencing Perimenopause and Menopause

NCT07619352
View directory record Official record
Conditions
Perimenopause, Menopause
Interventions
Navigating Menopause with a Mindfulness-Based Group Medical Visit
Other
Lead sponsor
Ohio State University
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 2, 2026, 10:42 PM EDT
Completed No phase listed Observational

The Effects of Estrogen Withdrawal on Mood Symptoms in Women

NCT00060736
View directory record Official record
Conditions
Perimenopausal Depression, Post Menopausal, Healthy, Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
45 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 2, 2026, 10:42 PM EDT
Completed Phase 3 Interventional Results available

Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

NCT02013544
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, Prasterone (DHEA)
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 80 Years · Female only
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 2, 2026, 10:42 PM EDT
Withdrawn Phase 2 Interventional

Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes

NCT06973109
View directory record Official record
Conditions
Osteoporosis, Post-menopausal
Interventions
Romosozumab, Alendronate (Fosamax), Placebo Romosozumab, Placebo Alendronate
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 2, 2026, 10:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Inorganic Nitrate and Intensity of Exercise on Cardiovascular Health in Post-Menopausal Females

NCT05221905
View directory record Official record
Conditions
Vascular Dilation, Arterial Stiffness
Interventions
BEET IT - Concentrate Beet root juice, BEET IT - Concentrate Beet root juice (nitrate depleted)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 2, 2026, 10:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)

NCT03608241
View directory record Official record
Conditions
Healthy Females
Interventions
PF-06651600, Ethinyl estradiol (EE) and levonogestrel (LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 2, 2026, 10:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Estrogen Variability and Irritability During the Menopause Transition

NCT05388656
View directory record Official record
Conditions
Menopause, Irritable Mood
Interventions
Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo, Progesterone 200 mg
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 59 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 2, 2026, 10:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health

NCT04001088
View directory record Official record
Conditions
Menopause
Interventions
Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Lallemand Health Solutions
Industry
Eligibility
40 Years to 59 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
5
States / cities
Lake Worth, Florida • Port Saint Lucie, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 2, 2026, 10:42 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

NCT00793546
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Bosutinib, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Lake Worth, Florida • Joliet, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2012 · Synced Sep 2, 2026, 10:42 PM EDT
Completed No phase listed Observational

Systemic Dickkopf-related Protein 1 (DKK1)During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors

NCT01431872
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 2, 2026, 10:42 PM EDT
Recruiting Not applicable Interventional

A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections

NCT06940622
View directory record Official record
Conditions
Recurrent UTIs, Recurrent Urinary Tract Infections, Recurrent Urinary Tract Infections in Women, Recurrent Urinary Tract Infection, Cystitis Recurrent, Cystitis Chronic, UTI, UTI - Urinary Tract Infection, UTI - Lower Urinary Tract Infection
Interventions
D-Mannose, Placebo
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years to 85 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 2, 2026, 10:42 PM EDT
Completed Phase 2 Interventional Results available

Exemestane in Post-Menopausal Women With NSCLC

NCT02666105
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Exemestane
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
18
States / cities
Albert Lea, Minnesota • Brainerd, Minnesota • Deer River, Minnesota + 14 more
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 2, 2026, 10:42 PM EDT
Not yet recruiting Phase 3 Interventional

Fezolinetant and Vascular Health and Brain Health

NCT07606664
View directory record Official record
Conditions
Menopause Hot Flashes
Interventions
Placebo, Fezolinetant
Drug
Lead sponsor
Rebecca Thurston
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 10:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

An Observational Study to Learn More About How Menopause Affects Women's Sleep and How They Are Being Treated for Sleep Problems

NCT06728332
View directory record Official record
Conditions
Sleep Disturbances Associated With Menopause
Interventions
No study intervention
Other
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 2, 2026, 10:42 PM EDT
Terminated Not applicable Interventional

The Effects of Lateralized Thermal Sleepwear on Sleep, Skin Temperature and Skin Moisture in Menopausal Women

NCT03037554
View directory record Official record
Conditions
Menopause Related Conditions
Interventions
Sleepwear with Lateralized Thermal Characteristics, Sham-Lateralized Sleepwear
Device
Lead sponsor
St. Peter's Hospital, Albany, NY
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 2, 2026, 10:42 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Effects of Soy Isoflavones on Menopausal Hot Flashes

NCT00179556
View directory record Official record
Conditions
Menopausal Symptoms
Interventions
Isoflavone supplement
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
38 Years to 65 Years · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 2, 2026, 10:42 PM EDT
Completed No phase listed Observational

Pragmatic Weight Loss Intervention During Menopause

NCT04487782
View directory record Official record
Conditions
Menopause, Menopause Related Conditions
Interventions
Focus Groups
Other
Lead sponsor
Kara Marlatt
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
55 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Sep 2, 2026, 10:42 PM EDT
Completed Phase 3 Interventional Results available

3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs

NCT00718861
View directory record Official record
Conditions
Post-menopausal Osteoporosis
Interventions
Placebo, Zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
10
States / cities
San Diego, California • Lakewood, Colorado • Gainesville, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Sep 2, 2026, 10:42 PM EDT
Withdrawn Phase 3 Interventional

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

NCT03619005
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder (HSDD)
Interventions
Placebo Vaginal Insert, Prasterone 6.5 mg (0.50%) Vaginal Insert
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Huntsville, Alabama • San Diego, California • New London, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 2, 2026, 10:42 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Effect of ZenRest™ Lotus Seed & Rice Germ Extract Blend on Sleep Quality in Menopausal Women

NCT07678359
View directory record Official record
Conditions
Sleep Quality, Menopause
Interventions
Lotus Seed & Rice Germ Extract, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraland USA, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 2, 2026, 10:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women

NCT00224094
View directory record Official record
Conditions
Menopause
Interventions
Premarin® (oral) vs. Alora® (transdermal)
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
42 Years to 70 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2012 · Synced Sep 2, 2026, 10:42 PM EDT